Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil for Emergence Agitation in Rhinoplasty
NCT06539013Recruiting
- Sponsor
- Gazi Yaşargil Training and Research Hospital
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of remifentanil in Emergence agitation (EA) (3 arms), sponsored by Gazi Yaşargil Training and Research Hospital. Primary endpoint: Richmond Agitation-Sedation Scale. Started Aug 2024; status: recruiting.
02
Drugs
remifentanil
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on NCT06539013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539013.